Seeking Alpha

The FDA's attempts to expedite drug approval may have undermined safety, an article in the...

The FDA's attempts to expedite drug approval may have undermined safety, an article in the Journal of the American Medical Association says. The authors, Thomas Moore and Curt Furberg, point to problems with Novartis' (NVS) Gilenya drug for multiple sclerosis, AstraZeneca's (AZN) Caprelsa for thyroid cancer and Boehringer Ingelheim's Pradaxa for stroke prevention.
Comments (2)
  • chopchop0
    , contributor
    Comments (3526) | Send Message
     
    Make the process longer and then people will complain about how expensive new drugs are, when they don't realize it can cost hundreds of millions of dollars to develop and test the safety and efficacy of many of these novel compounds.
    5 Sep 2012, 10:19 AM Reply Like
  • Jolt1
    , contributor
    Comments (6) | Send Message
     
    Furberg, the gadfly, is back at it once more.
    5 Sep 2012, 02:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector